Newly diagnosed multiple myeloma, transplant-eligible
Fit patients with newly diagnosed myeloma receive four drugs at once, then their own stem cells are collected, they are given high-dose chemotherapy, the cells are returned and they continue on maintenance. Adding the CD38 antibody daratumumab to the three-drug backbone, tested in PERSEUS and CASSIOPEIA, means most patients now reach a state where no myeloma can be detected.
Overview
Eligibility for autologous transplant rests on age, organ function and frailty rather than a fixed cut-off; most centres transplant to around 70 to 75. The sequence is three to six cycles of induction, stem cell mobilisation and collection, high-dose melphalan with autologous stem cell rescue, consolidation and then lenalidomide maintenance until progression. Two randomised trials settled the place of the transplant in the era of modern induction: IFM 2009 and DETERMINATION both showed a longer remission with early transplant after bortezomib-lenalidomide-dexamethasone (median progression-free survival 67.5 versus 46.2 months in DETERMINATION) but no survival difference, so delayed transplant at first relapse is an accepted choice.
Induction moved from triplets to quadruplets on the strength of CD38 antibodies. CASSIOPEIA (2019) added daratumumab to bortezomib-thalidomide-dexamethasone and raised stringent complete responses after consolidation from 20 to 29 percent while cutting progression or death by about half. PERSEUS (2024) added daratumumab to bortezomib-lenalidomide-dexamethasone around transplant with daratumumab-lenalidomide maintenance: progression-free survival at four years 84.3 percent versus 67.7 percent (hazard ratio 0.42), with three in four patients reaching MRD negativity at 10^-5, and daratumumab-VRd became the standard induction with regulatory approval in 2024. Isatuximab quadruplets (IsKia, GMMG-HD7) show the same pattern.
Maintenance with lenalidomide until progression lengthens life (Myeloma XI, CALGB 100104); whether to add a CD38 antibody, and whether MRD-negative patients can stop, are the questions of the MIDAS, DRAMMATIC and other MRD-adapted trials. The larger question is whether the transplant itself is still needed when quadruplets produce such deep responses, and CARTITUDE-6 is testing cilta-cel CAR-T in its place. High-risk cytogenetics (del(17p), t(4;14), t(14;16), gain or amplification of 1q) still predict early relapse and are treated with the deepest available regimens, sometimes with tandem transplant.
State of the art
- A daratumumab quadruplet around autologous transplant is standard after PERSEUS; most patients reach MRD negativity and more than eight in ten are progression-free at four years.
- Early transplant lengthens remission but not life compared with a deferred transplant, so both are offered.
- CAR-T in place of transplant and MRD-guided stopping of maintenance are under randomised test.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBlood clot (lenalidomide, pomalidomide, thalidomide)
A swollen painful calf, or sudden breathlessness with chest pain; venous and arterial thromboembolism is a boxed warning and blood-thinning prophylaxis is recommended.
- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Check before combiningLenalidomide with Dexamethasone: major interaction
Venous and arterial thromboembolism risk rises markedly with lenalidomide plus dexamethasone (and further with erythropoietin or oestrogens).. Thromboprophylaxis (aspirin, LMWH or a DOAC by risk) is standard.
- Check before combiningKidneys: Lenalidomide
Dose by creatinine clearance: 10 mg daily for CrCl 30-60, 15 mg every other day below 30, 5 mg daily on dialysis.
- Check before combiningLiver: Bortezomib
Start at 0.7 mg/m² in moderate or severe impairment.
- Good to knowInfusion reactions, hypersensitivity and extravasation
Reactions around the moment a drug is given: chills, fever or breathlessness from antibodies (infusion reactions), true allergy (hypersensitivity, rarely anaphylaxis), and leakage of a damaging drug into tissue around the vein (extravasation).
See all on the product pages:BortezomibDaratumumabDexamethasoneLenalidomideMelphalan (including hepatic delivery system)·Printable cards in the navigator
Anatomy and lymph node drainage
- Bone marrow (leukaemia, MDS, MPN, myeloma)
- Lymph node germinal centre (lymphomas)
- Spleen
- Blood (leukaemic phase)
- Lytic bone lesions (myeloma)
- Skin and extranodal sites
- Nodes: cervical
- Nodes: axillary
- Nodes: mediastinal
- Nodes: para-aortic and mesenteric
- Nodes: inguinal
Leukaemias, myeloma and MDS live in the marrow and blood; lymphomas grow in lymph nodes and spleen. The node stations are the disease map, not a route of spread, and staging counts them.
- Bone marrow (leukaemia, MDS, MPN, myeloma)Standard-risk transplant-eligible myeloma (R-ISS I or II without high-risk cytogenetics) · High-risk transplant-eligible myeloma (del(17p), t(4;14), t(14;16), gain 1q or R2-ISS high) · Transplant-deferred myeloma (stem cells collected, transplant kept for first relapse) · Light chain myeloma and IgA myeloma in fit patients
- Lymph node germinal centre (lymphomas)
- Spleen
- Blood (leukaemic phase)
- Lytic bone lesions (myeloma)
- Skin and extranodal sites
- cervical
- axillary
- mediastinal
- para-aortic and mesenteric
- inguinal
In lymphoma the node stations are the disease itself; staging (Ann Arbor / Lugano) counts how many regions and sides of the diaphragm are involved.
Same organ: Marginal zone lymphoma, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Primary mediastinal (thymic) large B-cell lymphoma, Leukaemia (all types), Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML), Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Non-Hodgkin lymphoma (all types), Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Polycythaemia vera (PV), Essential thrombocythaemia (ET), Waldenström macroglobulinaemia, Hairy cell leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Burkitt lymphoma, HIV-associated (AIDS-related) lymphomas, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Systemic mastocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, Langerhans cell histiocytosis (LCH), Post-transplant lymphoproliferative disorder (PTLD), FLT3-mutated acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute promyelocytic leukaemia, Acute myeloid leukaemia in older or unfit patients, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-ineligible, Relapsed or refractory multiple myeloma, Plasma cell leukaemia, Lower-risk myelodysplastic syndromes, Higher-risk myelodysplastic syndromes, Chronic lymphocytic leukaemia, first treatment, Relapsed or refractory chronic lymphocytic leukaemia, Richter transformation of chronic lymphocytic leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase, Primary myelofibrosis
Roughly four in ten people with newly diagnosed myeloma are fit enough for high-dose melphalan with an autologous stem cell transplant, generally those under about 70 without major organ disease.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Daratumumab plus bortezomib, lenalidomide and dexamethasone (PERSEUS) for four to six cycles; isatuximab-VRd or daratumumab-VTd (CASSIOPEIA) are alternatives.
High-dose melphalan with autologous stem cell transplant, early or deferred to first relapse after stem cell collection; tandem transplant considered in high-risk disease.
Lenalidomide until progression; daratumumab added after daratumumab-based induction (PERSEUS); bortezomib-containing maintenance in high-risk disease; MRD-guided stopping in trials.
M-protein and free light chains every cycle, MRD by sequencing or flow cytometry after transplant and during maintenance, imaging for residual focal lesions.
Subtypes & biomarkers
top- Standard-risk transplant-eligible myeloma (R-ISS I or II without high-risk cytogenetics)
- High-risk transplant-eligible myeloma (del(17p), t(4;14), t(14;16), gain 1q or R2-ISS high)
- Transplant-deferred myeloma (stem cells collected, transplant kept for first relapse)
- Light chain myeloma and IgA myeloma in fit patients
- R-ISS and R2-ISS stage
- FISH : del(17p), t(4;14), t(14;16), gain or amplification 1q
- Lactate dehydrogenase
- Serum free light chains and M-protein
- MRD by next-generation sequencing or flow cytometry at 10^-5 and 10^-6
- Frailty and organ function for transplant fitness
How often this target appears
- 1983McElwain: high-dose melphalan produces remissions in myeloma
- 1996IFM 90: autologous transplant beats conventional chemotherapy
- 2003Bortezomib approved; proteasome inhibition enters induction
- 2012Lenalidomide maintenance after transplant lengthens remission (IFM 2005-02, CALGB 100104)
- 2017IFM 2009: early transplant lengthens remission but not life after VRd
- 2019CASSIOPEIA: daratumumab quadruplet raises deep responses
- 2024PERSEUS: daratumumab-VRd around transplant approved as standard induction
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 9 changes by month →- 2026-09-17This recordNewly diagnosed multiple myeloma, transplant-eligibleFacts on this page last checked
When this page itself was last checked or edited.
- 2024MilestonePERSEUSPERSEUS: daratumumab-VRd around transplant approved as standard induction
A milestone in how this cancer is treated.
- 2023Trial resultPERSEUSPERSEUS reported
PFS HR 0.
- 2019MilestoneDaratumumabCASSIOPEIA: daratumumab quadruplet raises deep responses
A milestone in how this cancer is treated.
- 2017MilestoneVRd and Dara-VRd (myeloma induction regimens)IFM 2009: early transplant lengthens remission but not life after VRd
A milestone in how this cancer is treated.
- 2012MilestoneLenalidomideLenalidomide maintenance after transplant lengthens remission (IFM 2005-02, CALGB 100104)
A milestone in how this cancer is treated.
What is in development for Newly diagnosed multiple myeloma, transplant-eligible, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Trials under way · 1
- CARTITUDE-5 · phase 3 · Janssen
Trials reported · 1
- PERSEUS · phase 3 · 2023 · positive
Combinations being explored · 1
Ideas not yet in a trial · 2
Open problems and what is being done
Whether high-dose melphalan is still necessary after a quadruplet that produces MRD negativity.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- Autologous stem cell transplant (high-dose therapy)Standard of care
- Multiparameter flow cytometry MRDStandard of care
- NGS-based MRD (clonoSEQ and molecular MRD)Standard of care
In trialsNothing recorded yet.
Ideas and roadmapsBackground: MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶). Also on OnCo: Treatment journeys · Survivorship planner.
Whether MRD-negative patients can stop maintenance safely.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- Autologous stem cell transplant (high-dose therapy)Standard of care
- Multiparameter flow cytometry MRDStandard of care
- NGS-based MRD (clonoSEQ and molecular MRD)Standard of care
In trialsNothing recorded yet.
Ideas and roadmapsBackground: MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶). Also on OnCo: Treatment journeys · Survivorship planner.
High-risk cytogenetic disease still relapses early despite quadruplets.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- Autologous stem cell transplant (high-dose therapy)Standard of care
- Multiparameter flow cytometry MRDStandard of care
- NGS-based MRD (clonoSEQ and molecular MRD)Standard of care
In trialsNothing recorded yet.
Ideas and roadmapsBackground: MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶). Also on OnCo: Treatment journeys · Survivorship planner.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Rotterdam · consortium | Netherlands | none recorded | 1 | 8 | 207 | - | |
New Haven, CT · consortium | United States | none recorded | 0 | 2,224 | 28,423 | none recorded | - |
Beijing · hospital | China | none recorded | 0 | 1,154 | 11,808 | - | |
Jinan · cancer center | China | none recorded | 0 | 920 | 7,804 | - | |
Rotterdam · cancer center | Netherlands | none recorded | 0 | 852 | 12,180 | - | |
Würzburg · cancer center | Germany | none recorded | 0 | 760 | 11,806 | - | |
Basel · hospital | Switzerland | none recorded | 0 | 544 | 6,056 | - | |
Valencia · hospital | Spain | none recorded | 0 | 416 | 3,394 | - | |
Toronto, ON · hospital | Canada | none recorded | 0 | 264 | 4,071 | - | |
Nice · cancer center | France | none recorded | 0 | 249 | 3,204 | - | |
Amman · cancer center | Jordan | none recorded | 0 | 235 | 2,160 | - | |
Toulouse · cancer center | France | none recorded | 0 | 232 | 3,172 | - | |
Santiago · cancer center | Chile | none recorded | 0 | 95 | 3,048 | - | |
Cardiff · cancer center | United Kingdom | none recorded | 0 | 91 | 1,075 | - | |
Bangkok · cancer center | Thailand | none recorded | 0 | 61 | 907 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Newly diagnosed multiple myeloma, transplant-eligible but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Newly diagnosed multiple myeloma, transplant-eligible
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example R-ISS and R2-ISS stage, FISH: del, t, t, gain or amplification 1q, Lactate dehydrogenase, Serum free light chains and M-protein, MRD by next-generation sequencing or flow cytometry at 10^-5 and 10^-6), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Standard-risk transplant-eligible myeloma, High-risk transplant-eligible myeloma, t, t, gain 1q or R2-ISS high), Transplant-deferred myeloma.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Induction
- For my situation (induction), which of the standard options do you recommend and why?Why: Guideline options include: Daratumumab plus bortezomib, lenalidomide and dexamethasone (PERSEUS) for four to six cycles; isatuximab-VRd or daratumumab-VTd (CASSIOPEIA) are alternatives.
- Am I a candidate for Daratumumab, Bortezomib, Lenalidomide or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PERSEUS apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Consolidation
- For my situation (consolidation), which of the standard options do you recommend and why?Why: Guideline options include: High-dose melphalan with autologous stem cell transplant, early or deferred to first relapse after stem cell collection; tandem transplant considered in high-risk disease.
- Am I a candidate for Melphalan (including hepatic delivery system), and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Maintenance
- For my situation (maintenance), which of the standard options do you recommend and why?Why: Guideline options include: Lenalidomide until progression; daratumumab added after daratumumab-based induction (PERSEUS); bortezomib-containing maintenance in high-risk disease; MRD-guided stopping in trials.
- Am I a candidate for Lenalidomide, Daratumumab, Bortezomib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PERSEUS apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Response assessment
- For my situation (response assessment), which of the standard options do you recommend and why?Why: Guideline options include: M-protein and free light chains every cycle, MRD by sequencing or flow cytometry after transplant and during maintenance, imaging for residual focal lesions.
Any stage
- Are there clinical trials I could join, for example of Daratumumab, Isatuximab, Ciltacabtagene autoleucel, CARTITUDE-5?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “Whether high-dose melphalan is still necessary after a quadruplet that produces MRD negativity”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Whether MRD-negative patients can stop maintenance safely”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with Newly diagnosed multiple myeloma, transplant-eligible, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
13targets
4drugs
7companies
8terms
8trials
2pairings
1ideas
2Latest papers
topQuery for this cancer: (TITLE:"Newly diagnosed multiple myeloma, transplant-eligible" OR ABSTRACT:"Newly diagnosed multiple myeloma, transplant-eligible" OR TITLE:"Transplant-eligible myeloma" OR ABSTRACT:"Transplant-eligible myeloma" OR TITLE:"TE NDMM" OR ABSTRACT:"TE NDMM" OR TITLE:"Newly diagnosed myeloma, fit for autologous transplant" OR ABSTRACT:"Newly diagnosed myeloma, fit for autologous transplant") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Newly diagnosed multiple myeloma, transplant-eligible, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerNewly diagnosed multiple myeloma, transplant-ineligible
Shares Proteasome (PSMB5), R-ISS / R2-ISS staging, CARTITUDE-5, Cereblon (CRBN) and the tag subtype-page.
- CancerPlasma cell leukaemia
Shares Proteasome (PSMB5), High-risk cytogenetics (myeloma), Proteasome inhibitor (bortezomib, carfilzomib, ixazomib), Melphalan (including hepatic delivery system) and the tag subtype-page.
- CancerSmouldering multiple myeloma
Shares High-risk cytogenetics (myeloma), R-ISS / R2-ISS staging, Isatuximab, Whole-body MRI and the tag subtype-page.
- CancerRelapsed or refractory multiple myeloma
Shares Cereblon (CRBN), Proteasome inhibitor (bortezomib, carfilzomib, ixazomib), Immunomodulatory drugs (IMiDs) and CELMoDs, Isatuximab and the tag subtype-page.
- CancerAcute promyelocytic leukaemia
Shares Autologous stem cell transplant (high-dose therapy), Dexamethasone and the tag subtype-page.
- CancerRichter transformation of chronic lymphocytic leukaemia
Shares Autologous stem cell transplant (high-dose therapy), PET/CT and the tag subtype-page.
- CancerPrimary mediastinal (thymic) large B-cell lymphoma
Shares Autologous stem cell transplant (ASCT), Autologous stem cell transplant (high-dose therapy) and the tag subtype-page.
- CancerNon-seminomatous germ cell tumour
Shares Autologous stem cell transplant (high-dose therapy) and the tag subtype-page.